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Methods: The prepared solution of the injectable dosage form LCS-1208 is transferred to sterilizing filtration, which is carried out under vacuum on 
a «Stericup» filter unit with a filter pore size of 0.22 μm. The sterile solution of the injectable dosage form LCS-1208 is poured into sterile vials using 
a dispenser and lyophilized in a freeze-drying chamber. At the end of drying, the preparation is corked in the chamber of a sublimation unit using a 
hydraulic device and transferred to crimping with aluminum caps using a seaming machine. Quantitative determination of the drug content was 
determined by spectrophotometry using a standard sample at λ = 320±2 nm. The pH was determined by potentiometry.  
Development of a lyophilized injectable dosage form LCS-1208, an original antitumor drug based on an indolocarbazole derivative.  
Results: A freeze-drying regimen for the injectable dosage form LCS-1208 has been developed. The required solution freezing temperature was 
established taking into account the presence of 2 eutectic zones: a solution of LCS-1208 in DMSO (-35 ÷-32) °С, an aqueous solution of Kollidon 17PF 
(-10 ÷-8) °С. As a result of a series of experiments, the optimal lyophilization regime was chosen that does not require preliminary freezing in a low-
temperature chamber, with freezing on the shelves of freeze-drying at a temperature of-47 °C without their preliminary cooling. The most 
acceptable vial filling volume was determined, amounting to 3 ml, and the rate of temperature rise during secondary drying of the preparation was 
justified. When using the developed regime of lyophilization of the LCS-1208 solution, it was shown that it can be sublimated while preserving the 
initial qualitative and quantitative characteristics. 
Conclusion: In this article, using the example of creating a lyophilized injectable dosage form LCS-1208 (the original antitumor drug from the 
indolocarbazole group), the main problems that arose during the lyophilization of the selected composition of the model solution, as well as ways to 
improve the process.  
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Lyophilization is a process that has frequent problems at the stage of 
development and production of the dosage form; risks at control 
points are especially numerous. In this regard, there is a need to 
systematize knowledge and understanding of the components of this 
process, namely freezing and freeze-drying, mechanisms of heat and 
mass transfer processes occurring at different stages of lyophilization. 
The main ways to improve the lyophilization process is to optimize the 
technological aspects of drying and directly select auxiliary 
substances, based on the physicochemical basis of the process [
INTRODUCTION 
1-3
These approaches are considered by the example of the development 
of a lyophilized injection dosage form (ILF-lyo) LCS-1208, an original 
antitumor drug based on an indolocarbazole derivative [4]. 
]. 
The main influence on the quality of the finished dosage forms in the 
form of a lyophilisate for the preparation of a solution for injection is 
exerted by technological factors and excipients. Both are 
interconnected. So the composition and amount of excipients in 
lyophilization technology affect the choice of temperature 
conditions for freezing and freeze-drying, the stability of both the 
starting substance and the resulting product. For example, if the 
contents of the operating substance are small or significant, the 
subject of lyophilization is, it is small in water or water-alcohol 
mixture, a dosage form is introduced into the composition of the 
dosage form filler. In quality of such fillings, most often use high 
molecular weight compounds, polyvinylpyrrolidone (PVP) [5
Depending on the properties, these substances perform other 
functions: they affect the freezing process (for example, sugars, 
polymers, alcohols, lower the freezing point of water and slow down 
its crystallization), change the eutectic point, the drying speed and 
the final residual moisture [6
]; 
carbohydrates–sucrose, lactose; carbohydrate-containing alcohols–
mannitol, sorbitol; glycine and others. 
, 7
The first technological step in the production of injectable 
lyophilized drugs is to prepare a solution to be dried. In this regard, 
the physicochemical properties of the active substance 
(pharmaceutical substance) and possible ways of its destruction in 
the aquatic environment are studied, auxiliary components 
necessary in each specific case are selected [8]. 
]. 
The lyophilization process consists of three main stages. The first 
stage is freezing, which involves directly crystallizing the product 
and creating a strong matrix suitable for drying. 
The second stage is primary drying, which is sometimes preceded by 
an additional stage, called “annealing” or thermal cycling. Primary 
drying involves the removal of ice by sublimation while reducing the 
ambient pressure of the product and temperature [9, 10]. 
In the third stage–secondary drying–the bound water is removed 
until the residual moisture content reaches its target level, ensuring 
the integrity of the obtained lyophilisate tablet. [11-13]. 
The aim of this study was the development of a lyophilized 
injectable dosage form LCS-1208, an original antitumor drug based 
on an indolocarbazole derivative. 
Object of study 
MATERIALS AND METHODS 
In the studies, a model solution was used containing, as the active 
substance, the substance of the indolocarbazole derivative LCS-
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1208–6-amino-12-(1-α-L-arabinopyranosyl)indolo[2,3a]pyrrolo 
[3,4c] carbazole-5,7-dion created by specialists of the Research 
Institute of Experimental Diagnosis and Treatment of Tumors of the 
Federal State Budgetary Institution «N. N. Blokhin National Medical 
Research Centre of oncology» of the Health Ministry of Russian 
Federation (fig. 1). The substance LCS-1208 is soluble in water, 
slightly soluble in 95% alcohol and acetone, soluble in dimethyl 
sulfoxide (DMSO) and dimethylformamide. 
 
 




The solvent used was DMSO (Himmed, Russian Federation), the 
cryoprotectant and cosolvent was Kollidon 17 PF (PVP, povidone) 
(BASF The Chemical Company, Germany). 
Equipment 
Freeze-drying Minifast 10 (Edwards, Great Britain, Italy); low-
temperature chamber NZ 280/75. A (Frigera, Czech Republic); Cary 
100 spectrophotometer (Varian, Inc., Australia); HANNA pH meter 
pH 211 (Hanna Instruments, Germany); semiautomatic device PZR-
34-VIPS-MED for corking vials with caps K-2-20 and K-3-34 (LLC 
«ViPS-MED Company», Russian Federation); Stericup GP Millipore 
Express Plus filtration system with 0.22 μm polyethersulfone filters 
(Merck KGaA, Germany). 
Preparation of substance LCS-1208 
To 0.55 g (0.9 mmol) 13-formyl-12-(2,3,4-tri-O-acetyl-α-L-
arabinopyranosyl)indolo[2,3-a]furano[3,4-c]carbazole-5,7-dione 
added 3.2 ml (65.25 mmol) of hydrazine hydrate, the mixture was 
kept at 50 °C for two hours, cooled to 22 °C, poured into water. The 
precipitate was filtered off, washed with 10% alcohol. The yield of 6-
amino-12-(α-L-arabinopyranosyl)indolo[2,3-a]pyrrolo [3,4-
c]carbazole-5,7-dione was 0.37 g (89%). 
The optimal inject able dosage form (IDF) regimen LCS-1208 was 
chosen empirically after a series of experiments and subsequent 
physicochemical control of the finished product based on studies in 
different modes.  
RESULTS AND DISCUSSION 
In developing the optimal drying regime, LCS-1208 first investigated 
the effect of the initial temperature and its rise rate on the quality of 
the finished product, including its appearance, the preservation of 
the properties of the substance, the thickness of the initial solution 
layer, and the ability to rehydrate. To develop a lyophilization 
regime, the freezing conditions (its duration and method) of the LCS-
1208 model solution were initially selected, and the initial freezing 
temperature was determined for this purpose.  
When developing lyophilization technology to establish the required 
freezing temperature of a solution, it is necessary to determine the 
eutectic temperature, which has a specific value for each substance in the 
case of eutectic forming solutions or the eutectic zone for «glass-
forming» substances. Usually, the freezing temperature for reliability is 
taken 5–10 °C below the eutectic. The thermal method used to 
determine the eutectic temperature is the simplest. It is based on fixing 
the temperature of a sample frozen below a eutectic point during slow 
thawing. On the curve of measuring the temperature of the material 
upon reaching the eutectic point, a plateau is formed corresponding to 
the time when the heat supplied from outside does not increase the 
temperature but is spent on melting ice at a given eutectic 
«concentration» of the solution. Such a site can only be obtained with a 
sufficiently high content of the substance in the solution, therefore this 
method is not applicable in all cases. 
When determining the eutectic temperature, delamination of the 
frozen LCS-1208 model solution was observed. When the 
temperature reached (-42 ÷-40) °C, partial thawing was observed, 
and at (-35÷-32) °C, a bright yellow solution was formed in the 
lower layer of the frozen mass. The rest of the mass was thawed at a 
temperature of (-10 ÷-8) °С, which indicated the presence of 2 
eutectic zones. Obviously, a higher eutectic zone had an aqueous 
Kollidon 17PF solution, and at a lower one, the LCS-1208 solution 
distributed in it in DMSO froze. The difficulty of freezing and 
sublimation of this model solution is that DMSO is an antifreeze, 
therefore it freezes at very low temperatures. 
A key parameter in the final stage of primary drying is the selection of 
the optimal rate of heating of the lyophilisate. At low rates of heating and 
sublimation, the energy consumption of this stage increases, at high–the 
likelihood of destruction of the tablet by residual moisture increases. 
Therefore, to go to the secondary drying stage, a gradual slow 
temperature increase is necessary, which correlates with a change in the 
rate of evaporation of residual moisture. 
During secondary drying, the rate of temperature rise and the drying 
time of the product was studied. With the intensification of the 
secondary drying process by increasing the rate of temperature rise 
to+10 °C/h and increasing the temperature upon drying to+22 °C, a 
decrease in the content of the active substance LCS-1208 in the vial 
was observed below acceptable limits. Reducing the intensity of 
heating to 5 °C/h and increasing the drying time also did not provide 
guaranteed product quality.  
As a result of a visual assessment of the appearance of the 
accumulated batches of IDF LCS-1208 (with the maximum possible 
filling volume of the vials-6 ml) in accordance with the previously 
selected regime, it was found that thawed vials were found among 
the total mass of lyophilisates. In this regard, it was decided to 
choose the optimal volume of filling the vials with LCS-1208 solution 
and improve its lyophilization mode.  
For studies used the volume of filling the vials: 2, 3, 4, 5, 6 ml and 
various modes of lyophilization:  
1) with a preliminary long-term (12 h) freezing of the LCS-1208 
solution in a low-temperature chamber at a temperature of-45 °C 
and installation of vials on freeze-drying shelves, previously cooled 
for 1 hour at a temperature of-47 °C (mode 1); 
2) without preliminary freezing in a low-temperature chamber, with 
freezing at a temperature of-45 °C on shelves of freeze-drying, pre-
cooled for 1 hour at a temperature of-47 °C (mode 2); 
3) without preliminary freezing in a low-temperature chamber, with 
freezing on the shelves of freeze-drying at a temperature of-45 °C 
without their preliminary cooling (mode 3). 
Evaluated the effectiveness of the proposed regimes on the level of 
defective products (the number of melted vials in relation to the 
total number of dried vials), which was determined visually. As a 
result of a series of freeze-dried dryers, according to three modes 
with the different filling of the vials, it turned out that with filling 
volumes of 2 and 3 ml, the lyophilization regime did not affect the 
level of defective products; at the same time, the critical volume of 
filling the vials, which does not allow to ensure the absence of 
marriage–4 ml. Based on these results, the volume of 3 ml was 
chosen as the optimal one. Since the change in the freezing mode did 
not have a significant effect on the level of defective products, it was 
decided not to pre-freeze the LCS-1208 solution, but to cool the 
preparation on freeze-dried shelves without their preliminary 
cooling (mode 3).  
This mode was tested on a Minifast 10 freeze-dryer. Conducting 
lyophilization according to the selected mode on this unit provided a 
high-quality lyophilisate, which is a dry yellow porous mass, from a 
solution of 3 ml each. The solution obtained after dissolving the 
lyophilisate LCS-1208 is stable in terms of appearance, pH, and the 
content of the active substance during the day (sufficient for the use 
of the drug). 
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The results of preclinical studies IDF-lyo LCS-1208, conducted by 
employees of the N. N. Blokhin National Medical Research Centre of 
oncology are the optimal modes of application of the developed 
dosage form for tumors of various histogenesis (table 1) [14]. 
 
Table 1: Modes of use of IDF-lyo LCS-1208 for intravenous administration 
Transplanted tumors Dose The optimal mode of administration 
Hemoblastoses R-388 and L-1210 25 mg/kg daily intravenous administration (within 5 d) 
Fisher's lymphadenosis L 5178Y 
Lewis Epidermoid Carcinoma LLC 150 mg/kg single intravenous administration 
Cervical cancer CC-5 
Melanoma В-16 
 
The advantage of the lyophilized injectable dosage form LCS-1208 
on the duration of the antitumor effect was established compared 
with irinotecan, a well-known topoisomerase I inhibitor (table 2). 
The combination of LCS-1208 with irinotecan at doses half the 
therapeutic dose of combinants (75 mg/kg and 33 mg/kg, 
respectively) causes a synergistic antitumor effect [15]. 
 
Table 2: The advantage of IDF-lyo LCS-1208 on the duration of the antitumor effect compared with irinotecan 
Drug Tumor growth inhibition 
Within 20 d of treatment After treatment 
LCS-1208 95 % 94 % 
Irinotecan (Campto®–Pfizer (Perth) Pti Ltd.) 52 % 27% 
 
In the study of «acute» toxicity, it was found that with the use of IDF-
lyo LCS-1208 in a fixed concentration and the maximum possible 
volume intravenously in mice and intravenously and 
intraperitoneally to rats, no animal death was observed, therefore, 
the calculated toxic doses of IDF-lyo LCS-1208 were not obtained 
[16]. The subchronic toxicity of IDF-lyo LCS-1208 was studied with 
15-fold daily intraperitoneal administration to rats in total doses of 
50, 100 and 200 mg/kg for 15 d, which did not cause the death of 
animals, did not affect their general condition and did not cause 
external manifestations of toxicity [17]. Thus, the use of IDF-lyo LCS-
1208 is safe and may be recommended for further clinical studies. 
Based on experimental studies, the following technological 
processes (TP) were developed for obtaining a sterile solution LCS-
1208 and its further lyophilization:  
TP-1. Obtaining a sterile solution LCS-1208 
TP-1.1. Preparation of PVP solution 
In a glass cup with a capacity of 2 l, 1360 ml of water for injection is 
measured with a graduated cylinder. A portion of PVP (336.0 g), 
taken on an electronic balance in a glass beaker with a capacity of 1 
liter, is poured in parts onto a surface of the water, and the solution 
is mixed with a propeller stirrer, and then left to dissolve 
completely. Dissolution time about 20-30 min. 
TP-1.2. Preparation of LCS-1208 solution 
A portion of LCS-1208 5.04 g is weighed on an electronic balance in 
a glass glass with a capacity of 100 ml. 84.0 ml of DMSO measured by 
a cylinder was added to a LCS-1208 sample, mixed thoroughly with a 
glass rod. The resulting solution is added in portions to the PVP 
solution with constant stirring on a propeller stirrer. The LCS-1208 
solution is colored in orange and has a final volume of 1680 ml. 
Dissolution time 20-30 min. The solution is passed to the filtration. 
TP-1.3. LCS-1208 solution filtration and vial filling 
1.3.1. Sterilizing filtration solution LCS-1208 
Before filtering, the integrity of the filter is checked using a «bubble» 
test. The filter is considered to be intact and suitable for use if gas 
bubbles do not pass through the liquid layer when conducting a 
«bubble» test. Sterilizing filtration is carried out under vacuum on a 
«Stericup» filter unit with a filter pore size of 0.22 μm. Filtration time 
about 20-30 min. The resulting solution, which has an orange color, is 
transmitted for analysis. The filtered solution is passed to the bottling. 
TP-1.3.2. Bottling ster ile LCS-1208 solution in vials and pre-capping 
The sterile LCS-1208 solution is poured into 3.0 ml into sterile vials 
with a capacity of 20 ml using a dispenser. The first 4-5 doses of the 
solution, comprising 12-15 ml are discarded. Before bottling, check 
the correct operation of the dispenser. For this, 5 doses of the 
concentrate are measured in a dry graduated cylinder with a 
capacity of 25 ml. A deviation of±0.1 ml is allowed for a 3 ml 
solution. The correct operation of the dispenser is carried out 
periodically during the entire filling cycle (3-4 times). The LCS-1208 
solution used to test the dispenser is returned for repeated sterile 
filtration. Manual preliminary capping of the vials with the drug is 
carried out. Pre-sealed vials with a sterile LCS-1208 solution are 
placed in metal cassettes. Sensors are installed in two vials with LCS-
1208 solution and transferred for freezing. 
TP-2. Getting the finished product 
TP-2.1. Freezing 
Cassettes with vials are placed on the shelf of the Minifast 10 
sublimation unit, the sensors installed in the vials are connected, the 
chamber of the sublimation unit is closed and the product begins to 
freeze. Initial freezing temperature (-47 ÷-50) °С. After the 
temperature has been set on the preparation, the set temperature is 
held for 12-15 h. Monitoring temperature and duration of freezing 
by recording devices (vacuum gauge; six-channel recorder). 
TP-2.2. Freeze drying 
Initial drying temperature (-47 ÷-50) °С. Shelves are heated to a 
temperature of+20 °C 3 h after turning on the vacuum pump and 
equalizing the vacuum. The maximum possible rate of temperature 
rise is 1 °С/hour to a temperature of-25 °С. Then raise the 
temperature of the shelves 5 °С С/hour to a temperature of+20 °С. 
Duration of drying–from 3 to 5 h. After drying, air injection is 
switched on and the residual pressure in the chamber is adjusted to 
a value of 40-50 Pa. The temperature on the preparation during 
drying should not exceed+20 °С. The total drying time of the drug in 
vials with a capacity of 20 ml is 48-50 h. The control of the freeze-
drying process is carried out by the operator for the instruments 
and the recording device located on the installation panel. After 
drying, the vacuum in the sublimation chamber is quenched with 
clean, filtered air that enters the chamber through a filter system. 
The drug is corked in a sublimation chamber using a hydraulic 
device and transferred to crimping with aluminum caps. 
TP-2.3. Crimping with caps 
Crimping the vials with aluminum caps is carried out using a 
seaming machine in a room of cleanliness class B. Rolled vials are 
placed in cassettes and transferred to the stage of packaging and 
processing of finished products. 
A freeze-drying regimen for the injectable dosage form LCS-1208 
has been developed. The required solution freezing temperature 
CONCLUSION 
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was established taking into account the presence of 2 eutectic zones: 
a LCS-1208 solution in DMSO (-35 ÷-32) °С, an aqueous Kollidon 
17PF solution (-10 ÷-8) °С. As a result of a series of experiments, the 
optimal lyophilization regime was chosen that does not require 
preliminary freezing in a low-temperature chamber, with freezing 
on the shelves of freeze-drying at a temperature of-47 °C without 
their preliminary cooling. The most acceptable vial filling volume 
was determined, amounting to 3 ml, and the rate of temperature rise 
during secondary drying of the preparation was justified. Using the 
developed regime of lyophilization of the LCS-1208 solution, it was 
shown that it can be sublimated while maintaining the initial 
qualitative and quantitative characteristics. The results of preclinical 
and toxicological studies IDF-lyo LCS-1208, conducted by employees 
of the Research Institute of Experimental Diagnosis and Treatment 
of Tumors of the Federal State Budgetary Institution «N. N. Blokhin 
National Medical Research Centre of oncology» of the Health 
Ministry of Russian Federation, confirm the effectiveness and safety 
of the use of IDF-lyo LCS-1208 for further clinical studies. 
The work was performed as part of State contract No. 
13411.1008799.13.20 of 06.24.13. «Preclinical studies of innovative 
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